Cover Image
市場調查報告書

肺炎的診斷、治療:美國

Pneumonia - Diagnosis and Treatment Report

出版商 Boston Strategic Partners, Inc. 商品編碼 557100
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
肺炎的診斷、治療:美國 Pneumonia - Diagnosis and Treatment Report
出版日期: 2017年07月31日 內容資訊: 英文 88 Pages
簡介

本報告提供美國的肺炎的診斷、治療趨勢調查,患者的住院途徑與檢查、治療的流程,患者簡介,疾病的罹患率、住院期間、整體費用,原因的病原體,臨床檢驗和各種項目的週轉時間,主要的治療方法與使用藥物,主要藥物的市場佔有率,給藥統計,住院期間與死亡率,轉換期等各種資料、統計彙整。

患者的流程

摘要整理

罹患率、疾病的影響

  • 罹患率
  • 住院期間
  • 整體費用

患者人口統計

  • 年齡
  • 保險類型
  • 性別
  • 地區
  • 死亡率
  • 並存症

診斷檢驗的患者感染區分

  • 成為原因的病原體

各住院期間、費用:各患者屬性

  • 住院時的年齡
  • APACHE II評分
  • 初期治療環境

醫院的患者流動

  • 住院網站
  • 臨床檢驗
  • 週轉時間
  • 結果
  • 病因
  • 經驗性治療
  • 治療的變化

主要藥物的佔有率

  • 最常見的藥物
  • 住院日數
  • APACHE評分
  • 治療期間
  • 產品開發動態即時看板系統
    • 市場佔有率
    • 人口統計
    • 住院日數

治療的轉換期

  • 抗生素的使用
  • 死亡率
  • 每一患者的成本

藥物抗性肺炎

  • 目前趨勢
  • 成本
  • 並存症
  • 住院日數
  • 死亡率

資料庫概要

調查手法

目錄

In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals across the US, Boston Strategic Partners (BSP) Real World data report, Hospital-Treated Pneumonia , estimates 30% of all hospital discharges involve treatment of infectious organisms. Pneumonia is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for around $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of pneumonia patient characteristics, medication management, costs, and laboratory testing.

Hospital-Treated Pneumonia

Gram-negative bacteria are the likely causative agents of most pneumonia infections and physicians treat most of these patients with levofloxacin, ceftriaxone, and azithromycin. From 2010-2015, drug resistant organisms caused a surprising 20% of bacterial pneumonia infections.

This report provides quantitative, objective data using real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antibiotic resistant pathogens and antimicrobial stewardship.

Table of Contents

1. Patient Flow

2. Executive Summary

3. Incidence and Impact of Disease

  • Incidence
  • Length of Stay
  • Total Cost

4. Patient Demographics

  • Age
  • Insurance type
  • Gender
  • Region
  • Mortality
  • Comorbid Conditions

5. Patient Segmentation by Diagnostic Testing

  • Causative Etiologic Agent

6. Length of Stay and Cost by Patient Segment

  • Age at Admission
  • APACHE II Score
  • First Care Setting

7. Patient Flow through the Hospital

  • Admission Site
  • Lab Testing
  • Lab TAT
  • Results
  • Etiology
  • Empiric Therapy
  • Change in treatment

8. Drug Share for Key Therapeutics

  • Most Common
  • LOS
  • APACHE Score
  • Treatment Duration
  • Product Dashboards
    • Market Share
    • Demographics

9. Hospitalization

10. Outcomes of Treatment

  • Antibiotic Usage
  • Mortality
  • Cost per Patient

11. Drug Resistant Pneumonia

  • Current Trends
  • Costs
  • Comorbidity
  • LOS
  • Mortality

12. Database Overview

13. Methodology

Back to Top